UroGen Pharma Ltd. Revenue From Contract With Customer Excluding Assessed Tax

• UroGen Pharma Ltd. showed an increase of +21.4% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
• This data is from UroGen Pharma Ltd.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
• XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 9 years of available data (2017 to 2025), UroGen Pharma Ltd.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 1,245.8%.
• Historical annual values: Fiscal year 2025: $109.79 million | Fiscal year 2024: $90.40 million | Fiscal year 2023: $82.71 million | Fiscal year 2022: $64.36 million | Fiscal year 2021: $48.04 million | Fiscal year 2020: $11.80 million | Fiscal year 2019: $18.0 thousand | Fiscal year 2018: $1.13 million | Fiscal year 2017: $8.16 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026